glp 1 approved for nash mash and Novo's Wegovy becomes first GLP-1 drug Exploring the Potential of GLP-1 – Mechanisms of antidiabetic therapies for

Elkhalifa, A

Interestingly, a comparison of acute metabolic responses with the chronic profiles at the end of the treatment period strongly suggests that while the different GLP1-based agonists may share primary mechanisms of action, the durability and efficiency of their long-term metabolic responses differ, with clear superiority for the GLP1/E compound

Clinicians often advise stopping at about 75% of what feels like "full." Prioritize protein 2530 grams at each meal, aiming for at least 1.01.2 g per kg of body weight daily

Most of the clinical trials dont have even have a BMI requirement in the enrolment criteria

Almost 1 million prescriptions of these drugs were made in the US in December alone

Manstein, Assessing the impact of aging and blood pressure on dermal microvasculature by reactive hyperemia optical coherence tomography angiography